Skip to main content
. 2023 Aug 29;13:1227036. doi: 10.3389/fonc.2023.1227036

Table 3.

Univariate and multivariate analysis.

Parameters Univariate Multivariate (forward conditional)
Sig. Exp (B) 95% CI for Exp (B) Sig. Exp (B) 95% CI for Exp (B)
Male gender 0.852 0.951 0.564 1.606
Age 0.392 0.990 0.967 1.013
Bismuth I–II 0.881 Ref.
Bismuth III–IV 0.624 0.823 0.378 1.791
Distal CCA 0.923 1.051 0.385 2.867
Localization unknown 0.634 0.682 0.141 3.291
M0 vs. M1 0.523 0.968 0.874 1.071
Hepatic metastatic disease 0.955 1.027 0.408 2.587
ECOG 0 vs. >0 0.183 1.438 0.843 2.452
Total bilirubin (<1.5 vs. >1.5) 0.821 1.063 0.627 1.801
CA19-9 (<250 vs. >250) 0.268 0.737 0.430 1.264
MELD-Score (<6.5 vs. >6.5) 0.766 1.084 0.638 1.841
eRFA 0.021 0.515 0.293 0.905 0.037 0.416 0.183 0.947
ePDT 0.994 1.002 0.593 1.695
1 line vs. >1 line SC 0.030 0.523 0.291 0.939
No surgery 0.108 Ref.
Surgery with tumor resection 0.046 0.534 0.289 0.989
Surgery without tumor resection 0.043 0.348 0.125 0.966
Palliative surgery 0.660 0.822 0.343 1.971
R0 vs. R1 0.204 0.899 0.764 1.059
Metal stent implantation 0.006 0.416 0.223 0.777 0.037 0.406 0.174 0.948
ORR 0.800 0.907 0.426 1.932
DCR 0.027 0.526 0.297 0.930
First-line dose reduction over time 0.509 0.823 0.461 1.468
Tumor grading 1/2 vs. 3/4 0.020 2.260 1.138 4.489

CA19-9, carbohydrate antigen 19-9; CCA, cholangiocarcinoma; DCR, disease control rate; ECOG, Eastern Cooperative Oncology Group performance status; ePDT, endobiliary photodynamic therapy; eRFA, endobiliary radio-frequency ablation; MELD, model for end-stage liver disease; ORR, objective response rate; SC, systemic chemotherapy.Statistically significant P-Values are displayed in bold values.